Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis
NCT ID: NCT01012115
Last Updated: 2012-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2009-10-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Indicators of Inflammation and Coagulation in Sepsis
NCT01128283
Remote Ischemic Preconditioning in Septic Patients
NCT05830669
Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients
NCT01801501
Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey
NCT03179189
Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)
NCT00488917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be stratified into three groups:
* Sepsis
* SIRS of non-septic origin
* Other ICU patients
Routine laboratory data and clinical data (see flow sheet) will be collected. The plasma or serum will be frozen separately until the target number of patients is met. Measurements of inflammatory mediators and other cytokines/injury markers will be carried out at that point.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hemoglobin level \< 6.5 gm/dl
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oklahoma Medical Research Foundation
OTHER
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gary Kinasewitz
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary T Kinasewitz, MD
Role: PRINCIPAL_INVESTIGATOR
OU Health Sciences Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OU Medical Center
Oklahoma City, Oklahoma, United States
Veterans Affairs Medical Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14849
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.